Printer Friendly

AETHLON HEMOPURIFIER ADJUNCT THERAPY FOR HEPATITIS-C.

Aethlon Medical, Inc. (OTC Bulletin Board OTC Bulletin Board

An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system.
: AEMD), San Diego, has announced clinical data that supports the advancement of the Aethlon Hemopurifier(R) as an adjunct therapy to increase Hepatitis-C (HCV HCV
abbr.
hepatitis C virus


HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus.
) cure rates. The Hemopurifier(R) is a first-in-class medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. In HCV care, the device inhibits viral replication through selective elimination of HCV in circulation and assists to preserve immune cells by removing toxic proteins shed from the surface of HCV.

Aethlon disclosed that data resulting from over 20 HCV treatments indicates an average viral load reduction of 41% during each four-hour Hemopurifier(R) treatment. In the studies, average pre-treatment viral load of 22,868,000 HCV virus copies/ml blood (cpm) was reduced on average by 9,300,000 cpm during the course of each treatment. Based on this data, Aethlon predicts that short-term continuous Hemopurifier(R) treatment can reduce viral load to low to undetectable levels, thus improving the likelihood that HCV patients achieve a sustained virological response (SVR) from the current interferon-ribavirin standard of care and other candidate therapies. HCV infection is considered cured when SVR extends beyond six months. At present, less than 50% of HCV patients respond to interferon-ribavirin therapy. Additionally, there is a direct correlation between low viral load at onset of interferon-ribavirin therapy and increased cure rates. Based on data analyzed from each four-hour Hemopurifier(R) treatment, Aethlon projects that a patient with a high viral load of 7 million iu/ml would be reduced to undetectable HCV levels after approximately three days of continuous Hemopurifier(R) treatment. This corresponds to a 4.06 log reduction or an 11,000-fold decrease in viral load. An HCV patient with a moderate viral load of 2 million iu/ml would be projected to reach undetectable levels in approximately 2.5 days of continuous treatment. All of the studies were conducted in highly health compromised HCV infected patients who suffer from end-stage renal disease End-stage renal disease (ESRD)
Total kidney failure; chronic kidney failure is diagnosed as ESRD when kidney function falls to 5-10% of capacity.

Mentioned in: Chronic Kidney Failure

end-stage renal disease 
 (ESRD ESRD end-stage renal disease.
ESRD
End-stage renal disease; chronic or permanent kidney failure.

Mentioned in: Dialysis, Kidney

ESRD End-stage renal disease, see there
) requiring regular kidney dialysis treatment. In these treatment studies, the Hemopurifier(R) inhibited the progression of HCV infection in ESRD patients when included during dialysis treatment administered thrice weekly for four-hours. The studies were conducted at the Fortis Hospital in Delhi, India.

About Hepatitis-C Virus

HCV is a leading cause of chronic liver disease Chronic liver disease is a liver disease of slow process and persisting over a long period of time, resulting in a progressive destruction of the liver.

It includes amongst others:
  • Cirrhosis of the liver
  • Alcoholic liver disease
  • Chronic hepatitis C
 and liver transplants. The World Health Organization (WHO) estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with HCV. 130 million of these individuals are chronic HCV carriers who are at increased risk of developing liver cirrhosis or liver cancer, approximately 15 million of whom are in the United States, Europe and Japan. The CDC See Control Data, century date change and Back Orifice.

CDC - Control Data Corporation
 has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million were chronically infected. Approximately 2.6%, or 71,000, of these HCV patients are treated each year. Although chronic HCV infection varies greatly in its course and outcomes, 70% of chronically infected patients develop some form of chronic liver disease, including, in some cases, cirrhosis or liver cancer.

In the United States, the current standard of care for the treatment of HCV is a combination of pegylated interferon and a nucleoside analog named ribavirin. According to WHO, treatment with interferon in combination with ribavirin is effective in 30% to 50% of patients, while interferon alone is effective in approximately 10% to 20% of patients. In HCV genotypes 1a and 1b, which account for over 70% of HCV infections in the US, less than 50% of these patients respond to standard therapy consisting of pegylated interferon plus ribavirin. In addition, these therapies have serious side effects that include fatigue, bone marrow suppression Bone marrow suppression
A decrease in cells responsible for providing immunity, carrying oxygen, and those responsible for normal blood clotting.

Mentioned in: Cancer Therapy, Definitive

bone marrow suppression 
, anemia and neuropsychiatric neu·ro·psy·chi·a·try  
n.
The medical study of disorders with both neurological and psychiatric features.



neu
 effects. As a result of the limited benefits and serious side effects of existing therapies, significant value is placed on promising antiviral strategies to fight HCV. The Aethlon Hemopurifier(R) is positioned to improve the benefit of the current interferon-ribavirin standard of care, as well as other candidate HCV drug therapies demonstrating promise in clinical studies.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. Aethlon's lead product, the Hemopurifier(R), is a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus human immunodeficiency virus
n.
HIV.


Human immunodeficiency virus (HIV)
A transmissible retrovirus that causes AIDS in humans.
 (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds promise in cancer care, as research studies verify the Hemopurifier(R) effectively captures immunosuppressive exosomes that are secreted by tumors to kill-off immune cells. At present, over sixty-five (65) Hemopurifier(R) treatments (representing approximately 260 hours of treatment time) have been conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease (ESRD) patients infected with either HCV or HIV. In addition to establishing treatment safety, robust viral load reductions have been reported in both HCV and HIV infected individuals.

Research studies have also demonstrated the Hemopurifier(R) is effective in capturing a broad-spectrum of viruses untreatable with drug therapy, including several of world's deadliest bioterror and pandemic threats. These include: Dengue hemorrhagic fever (DHF DHF dihydrofolate or dihydrofolic acid. ), Ebola hemorrhagic fever Noun 1. Ebola hemorrhagic fever - a severe and often fatal disease in humans and nonhuman primates (monkeys and chimpanzees) caused by the Ebola virus; characterized by high fever and severe internal bleeding; can be spread from person to person; is largely limited to  (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the reconstructed 1918 influenza virus (r1918), West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis.  (WNV), and Vaccinia and Monkeypox (MPV (MusicPhotoVideo) A playlist standard for music, image and video collections introduced in 2002 by the Optical Storage Technology Association (OSTA). An "MPV Writer" is software that creates the playlist, and an "MPV Reader" is software that can discover and read it. ), which both serve as models for human smallpox infection. The studies were conducted with the assistance of researchers representing: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID USAMRIID United States Army Medical Research Institute of Infectious Diseases (US DoD) ); The Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center.  (CDC); The National Institute of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and The Southwest Foundation for Biomedical Research Southwest Foundation for Biomedical Research (SFBR) is a large private research institute located in San Antonio Texas.

With 400 staff and a 397 acre campus, SFBR is "one of the world's leading independent biomedical research institutions.
 (SFBR).

Beyond therapeutic market opportunities, Aethlon is leveraging principles underlying the Hemopurifier(R) technology platform to establish a pipeline of clinical and research diagnostic products and services.

For more information, visit http://www.aethlonmedical.com or call 858/459-7800, ext. 303.
COPYRIGHT 2009 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Date:May 1, 2009
Words:1022
Previous Article:MILLIPORE AWARDED EU PATENT IN RFID TECHNOLOGY.
Next Article:LASER-SINTERING ENABLES AUTOMATED MANUFACTURE OF CROWNS/BRIDGES.
Topics:


Related Articles
AETHLON MEDICAL SIGNS MAUFACTURING PARTNERSHIP.
INDIA AND CII SUPPORT AETHLON HIV/HEPATITIS TRIALS.
AETHLON MEDICAL LAUNCHES HEPATITIS-C CLINICAL TRIAL.
AETHLON EXPANDS DEVICE APPPICATIONS TO INCLUDE CANCER.
ATHELON HEMOPURIFIER REMOVES MORE THAN 99% OF DENGUE VIRUS.
AETHLON FILES PATENT ON HEMOPURIFIER USE FOR BIOMARKERS.
AETHLON MEDICAL HEMOPURIFIER FIRST-LINE FLU COUNTERMEASURE.
Aethlon Medical Provides Clinical Update at International Conference on Dialysis.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters